Key clinical point: Researchers developed a flow score based on three variables: developed a “flow score” with the three variables percentage of myeloid CD34 + cells > 2%; percentage of B-cell progenitors < 0.05%; and CD16 + monocytes/TNCs > 1.0%.
Major finding: Of the 95 patients in the study, 23 remained alive after the end of the study period. A high percentage of CD16 + monocytes/TNCs > 1.0% (in the highest quartile) was associated with significantly worse survival.
Study details: The data come from 95 adult patients with newly diagnosed myelodysplastic syndrome seen at a single center and followed for an average of 42 months.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Vido-Marques JR et al. Sci Rep. 2020 Nov 20. doi: 10.1038/s41598-020-77158-z .